Abstract: A diagnostic imaging support device includes: a learning unit that calculates a feature quantity about each of infectiousness condition and non-infectiousness condition for determining a condition in a determination image of an anterior eye through machine learning on the basis of a learning image of an anterior eye and information about a condition in the learning image.

Abstract: A control device includes a model generation unit that generates a control model that formulates a task to be executed, and a task processing unit that causes the vehicle to execute the task by performing model prediction control using the control model. Assuming that a first state space is a state space of the control model used at an execution time of the first task, and a second state space is a state space of the control model used at an execution time of the second task, the task processing unit starts to cause the vehicle to execute the second task, after executing a transition process that is a process of making a value of a state variable that is commonly included in both the first state space and the second state space within a predetermined range that is allowed at the execution time of the second task.

Abstract: An anti-MEFLIN antibody and a pharmaceutical composition comprising the antibody is described. The pharmaceutical composition may comprise an antibody-drug conjugate (ADC) of the anti-MEFLIN antibody and a cytotoxic agent, which may be connected to each other by a linker. The pharmaceutical composition may be used in the treatment of a cancer in a subject.

Abstract: A compound represented by the following formula (1A) or (1B): (the symbols in the formulae (1A) and (1B) have the same meaning as defined in the specification), an organic electroluminescent device containing the compound, and an electronic device including the organic electroluminescent device.

Abstract: An object of the present invention is to provide a polynucleotide having a modification site in a translated region with translation activity retained. The object can be achieved by a polynucleotide containing a translated region from a start codon to a stop codon, in which the translated region contains n codons, and the n is a positive integer of 2 or more, each of the n codons contains first, second and third nucleotides, and the first nucleotides in at least two codons of the n codons are sugar modified nucleotides.

Abstract: An actuator capable of attaining high output. The actuator includes a frame structure part that forms a frame structure surrounding a housing part, and a volume change part housed in the housing part. The volume change part increases a volume thereof by input of external energy. The frame structure part has a higher Young's modulus than a Young's modulus of the volume change part. The housing part has an anisotropic shape, with a maximum width in first direction of the housing part longer than a maximum width in second direction different from the first direction of the housing part.

Abstract: Provided is a method for preparing genetically-modified T cells expressing chimeric antigen receptor, comprising: (i) a step of preparing non-proliferative cells holding a viral peptide antigen, which are obtained by stimulating a group of cells comprising T cells using an anti-CD3 antibody and an anti-CD28 antibody followed by culturing in the presence of the viral peptide antigen and a treatment for causing the cells to lose their proliferation capability; (ii) a step of obtaining genetically-modified T cells into which a target antigen-specific chimeric antigen receptor gene has been introduced using a transposon method; (iii) a step of mixing the non-proliferative cells prepared by step (i) with the genetically-modified T cells obtained by step (ii), and co-culturing the mixed cells; and (iv) a step of collecting the cells after culture.

Abstract: Therapeutic methods and medicines may be developed by identifying a gene responsible for progressive supranuclear palsy, as may effective therapeutic methods and medicines. A medicine for progressive supranuclear palsy may contain a compound for inhibiting the expression of a filamin-A gene is provided. Also provided is an assessment system that uses cells expressing filamin-A, which is used in the search for medicaments for progressive supranuclear palsy or their candidates.

Abstract: A fiber-reinforced resin material includes: a first fiber-reinforced resin layer; a second fiber-reinforced resin layer having higher ductility and lower elasticity than those of the first fiber-reinforced resin layer; and a third fiber-reinforced resin layer having higher ductility and lower elasticity than those of the second fiber-reinforced resin layer. The first layer, the second layer, and the third layer are laminated and integrated in this order is made of the fiber-reinforced resin material. The manufacturing method includes: stacking a sheet-shaped product obtained by forming continuous fibers into a sheet shape and a resin sheet that serves as a first thermoplastic resin, a second thermoplastic resin, or a third thermoplastic resin so as to obtain a laminated structure in which the first layer, the second layer, and the third layer are laminated in this order; and heating and compressing the obtained stacked product in a stacking direction.

Abstract: Methods and apparatus for depositing carbon nanostructures such as three-dimensional graphene mesh using non-equilibrium gaseous plasma of high power density. Methods are disclosed for rapid deposition of randomly distributed graphene sheets on surfaces of substrates using decomposition of CO molecules of a high potential energy, and said excited CO molecules interacting with a substrate. The three-dimensional graphene mesh prepared according to the methods are useful in different applications such as light absorbents, fuel cells, super-capacitors, batteries, photovoltaic devices and sensors of specific gaseous molecules.

Abstract: A method of controlling movement of multi-vehicle includes acquiring a constraint condition under which vehicles move and a calculation cycle for calculating movement routes of the vehicles; acquiring a position of each vehicle; specifying a target position for each vehicle; calculating, based on the position of each vehicle, the target position, and the constraint condition, a movement route for prediction steps of each vehicle; determining, based on the movement routes of the vehicles, a driving condition of each vehicle from a current time to a unit time; and controlling movement of each vehicle. Calculating the movement route including performing optimization calculation based on an evaluation function, evaluation of which becomes higher as a deviation between the vehicle and the target position for each prediction step becomes smaller, and the constraint condition, to calculate the movement route.

Abstract: An agent for inhibiting the action of a target RNA based on RNA interference and ASO with a passenger strand and a guide strand for a target RNA, wherein both ends of double-stranded RNA formed pairing of the passenger strand and the guide strand are blunt ends, and one or two or more selected from the group consisting of the units represented by formula (1) and formula (2) below at the following positions (a) and (b): (a) 5? end side and 3? end side of the passenger strand, (b) 3? end side of the guide strand (in which X represents an oxygen atom or sulfur atom), (in which X represents an oxygen atom or sulfur atom).

Abstract: Provided is a method of producing semiconductor nanoparticles that exhibit a band-edge emission, and are superior in quantum yield. The method includes raising the temperature of a first mixture containing a silver (Ag) salt, a salt containing at least one of indium (In) and gallium (Ga), a solid compound that serves as a supply source of sulfur (S), and an organic solvent to a temperature in a range of from 125° C. to 175° C., and heat-treating, subsequent to the raising of the temperature, the first mixture at a temperature in a range of from 125° C. to 175° C. for three seconds or more to obtain a solution containing semiconductor nanoparticles, and decreasing the temperature of the solution containing semiconductor nanoparticles. The solid compound that serves as a supply source of S contains thiourea.

Abstract: In an energy system in a community provided with a plurality of unit grids, each of which is an energy transfer network of a single-unit facility including a power load, the unit grids each include a photovoltaic generator, supply power generated by the photovoltaic generator thereof to the power load thereof, and, as an electric vehicle moves, form a cooperative grid that transfers power stored in a mobile storage battery mounted on the electric vehicle to and from another of the unit grids, and some of the unit grids whose geographical positional relationship is not fixed form a virtual grid for transferring power as a combination of the unit grids that form the cooperative grids changes in accordance with a destination of the electric vehicle.

Abstract: A stacked body may include a support, a buffer layer, and an electrode layer, in this order, wherein the buffer layer may include one or more metals selected from the group consisting of Ga, Al, In, and Zn, and oxygen, the electrode layer comprises an oxide of magnesium and an oxide of zinc, and the electrode layer has a half width of a diffraction peak observed at 2?=34.8±0.5 deg in X-ray diffraction measurement of 0.43 deg or smaller.

Abstract: The purpose of the present invention is to provide a novel medical application using pluripotent stem cells in regenerative medicine. The present invention provides a cell formulation and pharmaceutical composition that are for amelioration and therapy for frequent urination and bladder pain caused by the inflammation of the bladder and that contain SSEA-3 positive pluripotent stem cells isolated from cultured mesenchymal cells or a mesenchymal tissue of a living organism. The cell formulation according to the present invention is considered to be based on a mechanism in which, for example, Muse cells are administered against interstitial cystitis having the abovementioned disorders to be successfully engrafted into affected bladder tissue, whereby the disorders are ameliorated and treated.

Abstract: Provided is a neutron beam transmission adjusting device including a neutron beam transmission unit including a neutron reactant and capable of modulating an energy and/or a flux of a neutron beam transmitted through the neutron beam transmission unit.

Abstract: In order to improve the efficiency of gene introduction in CAR therapy employing a transposon method, provided is a method for preparing genetically-modified T cells expressing chimeric antigen receptor, comprising: (1) a step of preparing non-proliferative cells which are obtained by stimulating a group of cells comprising T cells using an anti-CD3 antibody and an anti-CD28 antibody followed by a treatment for causing the cells to lose their proliferation capability; (2) a step of obtaining genetically-modified T cells into which a target antigen-specific chimeric antigen receptor gene has been introduced using a transposon method; (3) a step of mixing the non-proliferative cells prepared by step (1) with the genetically-modified T cells obtained by step (2), and co-culturing the mixed cells while stimulating the mixed cells using an anti-CD3 antibody and anti-CD28 antibody; and (4) a step of collecting the cells after culture.

Abstract: To provide a muscle tissue-regenerating agent containing a fibroin protein. A muscle tissue-regenerating agent containing a modified fibroin protein.

Abstract: An object is to provide a compound having ?-lactamase inhibitory activity. The object is achieved by a compound represented by formula (1), typified by a compound in which specific positions of a 5-membered ring having planarity are replaced by sulfamoyl and carboxy groups.